Clinical Trial 21061

Study Title

An Examination of Patient Reported Outcomes and Predictors Among Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors

Summary

Objective

Aim 1: Characterize PROs among a diverse sample of metastatic melanoma patients who have received SOC ICI treatment and compare PROs to those published from clinical trials. Aim 2: Test the proposed conceptual framework regarding the relationship between social determinants (predisposing factors), health behaviors (perpetuating factors), and PROs among metastatic melanoma patients who have received SOC ICI treatment (precipitating factor). Aim 3: Conduct qualitative interviews to explore patient perspectives of PROs, the impact of PROs on their daily lives, and further unmet needs not addressed in the questionnaire.